HomeProductsBuilding BlocksOrganic Building BlocksBenzene CompoundsMocravimod
Chemical structure of CAS 509092-16-4

Mocravimod

CAS No.509092-16-4
MDL No.N/A
MFC24H26ClNO3S
MW444.00
InChI KeyIINUNQPYJGJCJI-UHFFFAOYSA-N
CUSTOM SYNTHESISPRECLINICAL SUPPORT

Pricing & Availability

Pack SizePurityPriceAvailabilityAction
- -On RequestOn Request
Custom synthesis and bulk supply options are available upon request.

Product Information

CAS No.509092-16-4
Product NameMocravimod

Biological Targets

S1PR1

Associated Conditions

lymphoid neoplasm·ulcerative colitis·hematopoietic and lymphoid system neoplasm·cutaneous lupus erythematosus
* The information provided here is compiled from public sources and is for reference only.

Related Articles

Studies related to this compound and its mechanism of action

A Multicentre, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of the S1P Receptor Agonist KRP203 in Patients with Moderately Active Refractory Ulcerative Colitis.

Inflammatory intestinal diseases • Vol. 5, Issue 4 • 2020
PMID: 33313070PMC: PMC7706482DOI: 10.1159/000509393

The IUPHAR Guide to Immunopharmacology: connecting immunology and pharmacology.

Immunology • Vol. 160, Issue 1 • 2020
PMID: 32020584PMC: PMC7160657DOI: 10.1111/imm.13175

Use of sphingosine-1-phosphate 1 receptor agonist, KRP-203, in combination with a subtherapeutic dose of cyclosporine A for rat renal transplantation.

Transplantation • Vol. 82, Issue 6 • 2006
PMID: 17006328DOI: 10.1097/01.tp.0000232687.78242.cd

KRP-203, a novel synthetic immunosuppressant, prolongs graft survival and attenuates chronic rejection in rat skin and heart allografts.

Circulation • Vol. 111, Issue 2 • 2005
PMID: 15642767DOI: 10.1161/01.CIR.0000152101.41037.AB

Documentation

Similar Products